celecoxib has been researched along with Cachexia in 16 studies
Cachexia: General ill health, malnutrition, and weight loss, usually associated with chronic disease.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Previous studies reported promising efficacy for celecoxib in the treatment of cancer cachexia." | 9.27 | Randomized double-blind clinical trial of combined treatment with megestrol acetate plus celecoxib versus megestrol acetate alone in cachexia-anorexia syndrome induced by GI cancers. ( Ala, S; Alipour, A; Borhani, S; Janbabai, G; Kouchaki, B; Salehifar, E, 2018) |
| " antioxidants) with carnitine + celecoxib ± megestrol acetate for the treatment of cancer-related anorexia/cachexia syndrome (CACS): the primary endpoints were increase of lean body mass (LBM) and improvement of total daily physical activity." | 9.16 | Randomized phase III clinical trial of a combined treatment with carnitine + celecoxib ± megestrol acetate for patients with cancer-related anorexia/cachexia syndrome. ( Antoni, G; Astara, G; Cau, MC; Dessì, M; Macciò, A; Madeddu, C; Mantovani, G; Mela, Q; Montaldo, L; Mura, M; Panzone, F; Serpe, R; Tanca, FM, 2012) |
| " Patient compliance was very good; no patient had to reduce the celecoxib dosage nor interrupt treatment." | 6.75 | Phase II nonrandomized study of the efficacy and safety of COX-2 inhibitor celecoxib on patients with cancer cachexia. ( Antoni, G; Dessì, M; Macciò, A; Madeddu, C; Mantovani, G; Massa, E; Panzone, F; Serpe, R, 2010) |
| "Previous studies reported promising efficacy for celecoxib in the treatment of cancer cachexia." | 5.27 | Randomized double-blind clinical trial of combined treatment with megestrol acetate plus celecoxib versus megestrol acetate alone in cachexia-anorexia syndrome induced by GI cancers. ( Ala, S; Alipour, A; Borhani, S; Janbabai, G; Kouchaki, B; Salehifar, E, 2018) |
| " antioxidants) with carnitine + celecoxib ± megestrol acetate for the treatment of cancer-related anorexia/cachexia syndrome (CACS): the primary endpoints were increase of lean body mass (LBM) and improvement of total daily physical activity." | 5.16 | Randomized phase III clinical trial of a combined treatment with carnitine + celecoxib ± megestrol acetate for patients with cancer-related anorexia/cachexia syndrome. ( Antoni, G; Astara, G; Cau, MC; Dessì, M; Macciò, A; Madeddu, C; Mantovani, G; Mela, Q; Montaldo, L; Mura, M; Panzone, F; Serpe, R; Tanca, FM, 2012) |
| "Chronic inflammation is one of the main symptoms of cancer cachexia, and cyclooxygenase 2 inhibitors, such as celecoxib, may be beneficial in counteracting the major symptoms of this syndrome." | 3.81 | Celecoxib attenuates cachectic events in mice by modulating the expression of vascular endothelial growth factor. ( Bi, Y; Han, M; Jiang, M; Xu, X; Zhang, Y, 2015) |
| "It has been suggested that the optimal treatment for cachexia should be a multimodal intervention." | 2.84 | A randomized phase II feasibility trial of a multimodal intervention for the management of cachexia in lung and pancreatic cancer. ( Balstad, TR; Bye, A; Fallon, M; Fayers, P; Fearon, K; Johns, N; Kaasa, S; Laird, BJA; Pettersen, CH; Solheim, TS; Stene, GB, 2017) |
| "Cancer cachexia is a syndrome of progressive weight loss." | 2.76 | A randomised feasibility study of EPA and Cox-2 inhibitor (Celebrex) versus EPA, Cox-2 inhibitor (Celebrex), resistance training followed by ingestion of essential amino acids high in leucine in NSCLC cachectic patients--ACCeRT study. ( Bird, SP; Keogh, JW; MacLeod, RD; Rogers, ES; Stewart, J, 2011) |
| " Patient compliance was very good; no patient had to reduce the celecoxib dosage nor interrupt treatment." | 2.75 | Phase II nonrandomized study of the efficacy and safety of COX-2 inhibitor celecoxib on patients with cancer cachexia. ( Antoni, G; Dessì, M; Macciò, A; Madeddu, C; Mantovani, G; Massa, E; Panzone, F; Serpe, R, 2010) |
| "Cancer cachexia is a devastating syndrome of advanced malignancy which negatively impacts on patients' morbidity, mortality and quality of life." | 2.49 | Non-steroidal anti-inflammatory drugs for the treatment of cancer cachexia: a systematic review. ( Cantwell, MM; Hughes, CM; Murray, LJ; Parsons, C; Reid, J, 2013) |
| "Celecoxib treatment prevented the losses in body mass and mass of retroperitoneal adipose tissue, gastrocnemius, and extensor digitorum longus muscles in tumor-bearing rats." | 1.42 | Effects of celecoxib and ibuprofen on metabolic disorders induced by Walker-256 tumor in rats. ( Borba-Murad, GR; de Andrade, FG; de Fatima Silva, F; de Morais, H; de Souza, CO; de Souza, HM; Kurauti, MA, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (25.00) | 29.6817 |
| 2010's | 12 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Solheim, TS | 1 |
| Laird, BJA | 1 |
| Balstad, TR | 1 |
| Stene, GB | 1 |
| Bye, A | 1 |
| Johns, N | 1 |
| Pettersen, CH | 1 |
| Fallon, M | 1 |
| Fayers, P | 1 |
| Fearon, K | 1 |
| Kaasa, S | 1 |
| Kouchaki, B | 1 |
| Janbabai, G | 1 |
| Alipour, A | 1 |
| Ala, S | 1 |
| Borhani, S | 1 |
| Salehifar, E | 1 |
| Xu, X | 1 |
| Jiang, M | 1 |
| Zhang, Y | 1 |
| Bi, Y | 1 |
| Han, M | 1 |
| de Souza, CO | 1 |
| Kurauti, MA | 1 |
| de Fatima Silva, F | 1 |
| de Morais, H | 1 |
| Borba-Murad, GR | 1 |
| de Andrade, FG | 1 |
| de Souza, HM | 1 |
| Macciò, A | 5 |
| Gramignano, G | 3 |
| Madeddu, C | 5 |
| Mantovani, G | 4 |
| Serpe, R | 3 |
| Antoni, G | 2 |
| Massa, E | 2 |
| Dessì, M | 2 |
| Panzone, F | 3 |
| von Haehling, S | 1 |
| Stepney, R | 1 |
| Anker, SD | 1 |
| Romero, FI | 1 |
| Martínez-Calatrava, MJ | 1 |
| Sánchez-Pernaute, O | 1 |
| Gualillo, O | 1 |
| Largo, R | 1 |
| Herrero-Beaumont, G | 1 |
| Cau, MC | 2 |
| Montaldo, L | 1 |
| Mela, Q | 1 |
| Mura, M | 1 |
| Astara, G | 2 |
| Tanca, FM | 1 |
| Rogers, ES | 1 |
| MacLeod, RD | 1 |
| Stewart, J | 1 |
| Bird, SP | 1 |
| Keogh, JW | 1 |
| Mulas, C | 1 |
| Floris, C | 1 |
| Sanna, E | 1 |
| Reid, J | 1 |
| Hughes, CM | 1 |
| Murray, LJ | 1 |
| Parsons, C | 1 |
| Cantwell, MM | 1 |
| Cerchietti, LC | 2 |
| Navigante, AH | 2 |
| Peluffo, GD | 1 |
| Diament, MJ | 1 |
| Stillitani, I | 1 |
| Klein, SA | 1 |
| Cabalar, ME | 1 |
| Lusso, MR | 1 |
| Deiana, L | 1 |
| Lai, V | 1 |
| George, J | 1 |
| Richey, L | 1 |
| Kim, HJ | 1 |
| Cannon, T | 1 |
| Shores, C | 1 |
| Couch, M | 1 |
| Castro, MA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Feasibility Study of Multimodal Exercise/Nutrition/Anti-inflammatory Treatment for Cachexia - the Pre-MENAC Study[NCT01419145] | 46 participants (Actual) | Interventional | 2011-10-31 | Completed | |||
| Megestrol Acetate for the Improvement of Quality of Life in Esophageal Cancer With Chemoradiotherapy[NCT02644408] | Phase 3 | 184 participants (Actual) | Interventional | 2014-10-01 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for celecoxib and Cachexia
| Article | Year |
|---|---|
Non-steroidal anti-inflammatory drugs for the treatment of cancer cachexia: a systematic review.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Body Weight; Cachexia; Celecoxib; Cyclooxygenase 2 I | 2013 |
10 trials available for celecoxib and Cachexia
| Article | Year |
|---|---|
A randomized phase II feasibility trial of a multimodal intervention for the management of cachexia in lung and pancreatic cancer.
Topics: Aged; Cachexia; Celecoxib; Combined Modality Therapy; Dietary Supplements; Disease Management; Exerc | 2017 |
Randomized double-blind clinical trial of combined treatment with megestrol acetate plus celecoxib versus megestrol acetate alone in cachexia-anorexia syndrome induced by GI cancers.
Topics: Anorexia; Antineoplastic Agents, Hormonal; Cachexia; Celecoxib; Combined Modality Therapy; Double-Bl | 2018 |
Phase II nonrandomized study of the efficacy and safety of COX-2 inhibitor celecoxib on patients with cancer cachexia.
Topics: Aged; Cachexia; Celecoxib; Cyclooxygenase 2 Inhibitors; Female; Humans; Middle Aged; Neoplasms; Pyra | 2010 |
Randomized phase III clinical trial of a combined treatment with carnitine + celecoxib ± megestrol acetate for patients with cancer-related anorexia/cachexia syndrome.
Topics: Absorptiometry, Photon; Aged; Aged, 80 and over; Anorexia; Appetite; Cachexia; Carnitine; Celecoxib; | 2012 |
A randomised feasibility study of EPA and Cox-2 inhibitor (Celebrex) versus EPA, Cox-2 inhibitor (Celebrex), resistance training followed by ingestion of essential amino acids high in leucine in NSCLC cachectic patients--ACCeRT study.
Topics: Adult; Amino Acids, Essential; Cachexia; Carcinoma, Non-Small-Cell Lung; Celecoxib; Combined Modalit | 2011 |
A randomized phase III clinical trial of a combined treatment for cachexia in patients with gynecological cancers: evaluating the impact on metabolic and inflammatory profiles and quality of life.
Topics: Adult; Aged; Antioxidants; Cachexia; Carnitine; Celecoxib; Female; Genital Neoplasms, Female; Humans | 2012 |
Effects of celecoxib, medroxyprogesterone, and dietary intervention on systemic syndromes in patients with advanced lung adenocarcinoma: a pilot study.
Topics: Adenocarcinoma; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Cachexi | 2004 |
A phase II study with antioxidants, both in the diet and supplemented, pharmaconutritional support, progestagen, and anti-cyclooxygenase-2 showing efficacy and safety in patients with cancer-related anorexia/cachexia and oxidative stress.
Topics: Adult; Aged; Anorexia; Ascorbic Acid; Cachexia; Carbocysteine; Celecoxib; Dietary Supplements; Docos | 2006 |
Results of a pilot study of the effects of celecoxib on cancer cachexia in patients with cancer of the head, neck, and gastrointestinal tract.
Topics: Body Mass Index; Body Weight; C-Reactive Protein; Cachexia; Celecoxib; Cyclooxygenase Inhibitors; Cy | 2008 |
Effects of eicosapentaenoic and docosahexaenoic n-3 fatty acids from fish oil and preferential Cox-2 inhibition on systemic syndromes in patients with advanced lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Appetite; C-Reactive Protein; Cachexia; Celecoxib; Cohort Studies; C | 2007 |
5 other studies available for celecoxib and Cachexia
| Article | Year |
|---|---|
Celecoxib attenuates cachectic events in mice by modulating the expression of vascular endothelial growth factor.
Topics: Anemia; Animals; Antibodies, Monoclonal; Body Weight; Cachexia; Celecoxib; Cell Line, Tumor; Cycloox | 2015 |
Effects of celecoxib and ibuprofen on metabolic disorders induced by Walker-256 tumor in rats.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Area Under Curve; Cachexia; Carcinoma 256, Walker; | 2015 |
Surprising results of a supportive integrated therapy in myelofibrosis.
Topics: Anemia; C-Reactive Protein; Cachexia; Carnitine; Celecoxib; Curcumin; Erythropoietin; Fatigue; Ferri | 2015 |
Advances in understanding and treating cardiac cachexia: highlights from the 5th Cachexia Conference.
Topics: Anabolic Agents; Animals; Appetite Stimulants; Cachexia; Celecoxib; Congresses as Topic; Drug Therap | 2010 |
Pharmacological modulation by celecoxib of cachexia associated with experimental arthritis and atherosclerosis in rabbits.
Topics: Animals; Arthritis, Experimental; Arthritis, Rheumatoid; Atherosclerosis; Cachexia; Celecoxib; Cyclo | 2010 |